• Norfloxacin bested placebo in reducing mortality in HCV cirrhosis

    4 monthes ago - By Healio

    AMSTERDAM - Norfloxacin yielded improved 6-month survival compared with placebo in a cohort of HCV patients with Child-Pugh C cirrhosis, according to data presented at the International Liver Congress.“In this trial involving patients with Child-Pugh C cirrhosis without recent history of fluoroquinolone therapy, 6-month mortality was significantly lower among patients who received norfloxacin than among those who received placebo,” Richard Moreau, MD, of APHP, DHU UNITY, Service d'Hépatologie, Hôpital Beaujon, Centre de Recherche sur l'Inflammation in Paris, said during a press conference...
    Read more ...